“DO YOU HEAR WHAT WE HEAR?”

BECAUSE…

“IT’S BEGINNING TO LOOK A LOT LIKE…CONSPIRACY”

The GRINCH DEFENDANTS want to THROW OUT your ZANTAC CLIENT CASES!

LEARN HOW TO PROTECT YOUR ZANTAC CLIENTS NOW.

WHITEBOARD WEDNESDAY ON DECEMBER 16TH IS AN ABSOLUTE MUST FOR YOUR ZANTAC/RANITIDINE CASES.

With over 50,000 Zantac/Ranitidine cases and growing, the GRINCH DEFENDANTS are worried. They know this will be a massive MDL and they want to throw out as many cases as possible initially!

The DEFENDANTS will be actively attempting to have your Plaintiff’s cases thrown out by claiming that they have ceased marketing that particular Zantac/Ranitidine product based on their “end marketing” dates.

Go on a “SLAY RIDE” with John Ray and learn HOW TO COUNTER THIS DEFENDANT TACTIC AND SAVE YOUR CASES. Sign up for Whiteboard Wednesday on 12/16 (2PM-4PM EST).

Mass Tort Nexus has unraveled and uncovered a far-reaching CONSPIRACY (and identified the major conspirators) that produced, packaged, distributed and sold approximately 1,000 various Ranitidine products by employing a scheme involving obtaining multiple National Drug Code’s (NDC), for finished products with branding and labeling that was never approved by the FDA and for that matter, could not be approved by the FDA. Per (21 CFR §207.37 (a)(2)

SUM AND SUBTANCE. THRU THE MANIPULATION OF NDC CODES, COUNTERFEIT GENERIC “BRANDS” WERE PRODUCED AND SOLD BY THE GRINCH DEFENDANTS WITHOUT FDA APPROVAL.

ONCE YOU UNDERSTAND THE LAWS/REGULATIONS SURROUNDING THIS, YOU WILL BE ARMED TO IDENTIFY A COUNTERFEIT RANITIDINE PRODUCT IN VIOLATION OF 21 U.S. Code § 331. THRU REVIEW OF THE SPL (STRUCTED PRODUCT LABELING) INFORMATION AND OTHER EVIDENCE IN OUR POSESSION. WITH THIS INTELLIGENCE, YOU WILL BE READY TO DISCREDIT ANY AVERMENTS OF THESE GRINCH DEFENDANTS CLAIMING THAT THEY HAD CEASED “END” MARKETING A GIVEN PRODUCT AT THE TIME YOUR CLIENT CLAIMS TO HAVE PURCHASED IT.

ALL of this ground-breaking information will be discussed in further detail on the Zantac/Ranitidine Whiteboard Wednesday (2PM-4PM EST).

WE ARE ALMOST “MAX’ED” OUT- ONLY A FEW SPACES LEFT.

Read More

BAH HUMBUG! The Zantac DEFENDANTS want to silence your clients and throw their cases out!

TIME TO LEAN IN AND LEARN HOW TO PROTECT YOUR ZANTAC INVESTMENT NOW.

WHITEBOARD WEDNESDAY ON DECEMBER 16TH IS AN ABSOLUTE MUST FOR YOUR ZANTAC/RANITIDINE CASES.

With over 50,000 Zantac/Ranitidine cases and growing, the SCROOGE DEFENDANTS are worried. They know this will be a massive MDL and they want to throw out as many cases initially as possible!… “WE SEE A VACANT SEAT…WHERE YOUR CASES ONCE WERE”!

The DEFENDANTS will be actively attempting to have your Plaintiff’s cases thrown out by claiming that they have ceased marketing that particular Zantac/Ranitidine product based on their “end marketing” dates. YOU WILL UNDERSTAND HOW TO COUNTER THIS TACTIC AND SAVE YOUR CASES after participating in Whiteboard Wednesday on 12/16 (2PM-4PM EST).

IT’S SHOCKING AND ILLEGAL!

Mass Tort Nexus has unraveled and uncovered a far-reaching CONSPIRACY (and identified the major conspirators) that produced, packaged, distributed and sold approximately 1,000 various Ranitidine products by employing a scheme involving obtaining multiple National Drug Code’s (NDC), for finished products with branding and labeling that was never approved by the FDA and for that matter, could not be approved by the FDA. Per (21 CFR §207.37 (a)(2)

SUM AND SUBTANCE. THRU THE MANIPULATION OF NDC CODES, COUNTERFEIT GENERIC “BRANDS” WERE PRODUCED AND SOLD BY THE DEFENDANTS WITHOUT FDA APPROVAL.

ONCE YOU UNDERSTAND THE LAWS/REGULATIONS SURROUNDING THIS, YOU WILL BE ARMED TO IDENTIFY A COUNTERFEIT RANITIDINE PRODUCT IN VIOLATION OF 21 U.S. Code § 331. THRU REVIEW OF THE SPL (STRUCTED PRODUCT LABELING) INFORMATION AND OTHER EVIDENCE IN OUR POSESSION. WITH THIS INTELLIGENCE, YOU WILL BE READY TO DISCREDIT ANY AVERMENTS OF THESE DEFENDANTS CLAIMING THAT THEY HAD CEASED “END” MARKETING A GIVEN PRODUCT AT THE TIME YOUR CLIENT CLAIMS TO HAVE PURCHASED IT.

To provide clarity on WHAT THE SCROOGE DEFENDANTS ARE HIDING, you will receive John Ray’s White Paper prior to 12/16 for your review AND all of this ground-breaking information will be discussed in further detail on the Zantac/Ranitidine Whiteboard Wednesday (2PM-4PM EST).

“No space of regret can make amends for one’s opportunity misused!”

 

Read More

THE ZANTAC DEFENDANTS ARE DETERMINED TO THROW OUT YOUR CASES!

HOW TO PREVENT DISMISSAL OF YOUR GENERIC ZANTAC CASES

OUR WHITEBOARD WEDNESDAY ON DECEMBER 16TH IS AN ABSOLUTE MUST FOR YOUR ZANTAC CASES.

Are you aware that the DEFENDANTS will be actively attempting to have your Plaintiff’s cases thrown out by claiming that they have stopped marketing that particular Zantac/Ranitidine product based on their “end marketing” dates. YOU WILL UNDERSTAND HOW TO COUNTER THIS TACTIC AND SAVE YOUR CASES after participating in Whiteboard Wednesday on 12/16 (2PM-4PM EST).

Mass Tort Nexus has unraveled and uncovered a far-reaching CONSPIRACY (and identified the major conspirators) that produced, packaged, distributed and sold approximately 1,000 various Ranitidine products by employing a scheme involving obtaining multiple National Drug Code’s (NDC), for finished products with branding and labeling that was never approved by the FDA and for that matter, could not be approved by the FDA. Per (21 CFR §207.37 (a)(2), Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that “creates an impression of official approval because of possession of an NDC number is misleading and constitutes misbranding.

IT’S A BOMBSHELL!

In a nutshell, a single Ranitidine drug maker would obtain FDA approval for the generic (ANDA) that included labeling for a single finished product, (in various sizes/counts) for sale to a retail class of consumers. That drug maker would then fill and ship large containers (drums of up to 60,000 pills) to a repackaging company. The repackaging company would repackage at a smaller scale with retail store branding and labeling. This “repackaging” was never approved by the FDA. These are counterfeit finished drugs. Under NO circumstances is a repackaged product to end up on a retail shelf as an OTC drug in any store…it is illegal.

The creation of counterfeit finished drug products as described above, is a Federal crime. In violation of 21 U.S. Code § 331 (k), § 331 (a) and § 331 (b) and is punishable under of 21 U.S. Code § 333 by up to 10 years in prison and a $10,000.00 fine for each individual unit of product entered into the stream of commerce.

ONCE YOU UNDERSTAND THE LAWS/REGULATIONS SURROUNDING THIS, YOU WILL BE ARMED TO IDENTIFY A COUNTERFEIT RANITIDINE PRODUCT IN VIOLATION OF 21 U.S. Code § 331. THRU REVIEW OF THE SPL (STRUCTED PRODUCT LABELING) INFORMATION AND OTHER EVIDENCE IN OUR POSESSION. WITH THIS INFORMATION AND EVIDENCE IN HAND, YOU WILL BE ABLE TO DISCREDIT ANY AVERMENTS OF THESE DEFENDANTS CLAIMING THAT THEY HAD CEASED MARKETING A GIVEN PRODUCT AT THE TIME YOUR CLIENT CLAIMS TO HAVE PURCHASED THAT PRODUCT.

To provide clarity on WHAT THE DEFENDANTS ARE HIDING, you will receive John Ray’s White Paper prior to 12/16 for your review AND all of this ground-breaking information will be discussed in further detail on the Zantac/Ranitidine Whiteboard Wednesday (2PM-4PM EST).

REGISTER NOW-WE ARE APPROACHING CAPACITY.

Read More

HOW TO PREVENT DISMISSAL OF YOUR GENERIC ZANTAC CASES

OUR WHITEBOARD WEDNESDAY ON DECEMBER 16TH IS CRUCIAL TO YOUR ZANTAC MDL CASES.

To date, there are more than 50,000 cases filed into the Zantac/Ranitidine MDL.

Are you aware that the DEFENDANTS will be actively attempting to have your Plaintiff’s cases thrown out by claiming that they have stopped marketing that particular Ranitidine product based on their “end marketing” dates. YOU WILL UNDERSTAND HOW TO COUNTER THIS TACTIC AND SAVE YOUR CASES after participating in Whiteboard Wednesday.

MTN has unraveled a far-reaching conspiracy (and identified the major conspirators) that produced, packaged, distributed and sold approximately 1,000 various Ranitidine products by employing a scheme involving obtaining multiple National Drug Code’s, for finished products with branding and labeling that was never approved by the FDA and for that matter, could not be approved by the FDA.

Although the appearance of an NDC code on a finished drug product might lead a consumer to believe that product, as labeled, was approved by the FDA, nothing could be further from the truth.

Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of official approval because of possession of an NDC number is misleading and constitutes misbranding. (21 CFR §207.37 (a)(2))

This is how the scheme worked: A single drug maker would obtain ANDA approval, including the labeling for a single finished product, in various sizes or counts appropriate for sale to a retail class of consumers. That ANDA holder would then fill large containers, up to drums of 60,000 pills, which would be shipped to a repacking company. The repacking company would remove the pills from the bulk containers and fill containers with retail store branding and labeling not approved by the FDA.

The narrow allowance for repackaging approved drug products is limited to the ANDA or NDA holder allows repacking entity to produce containers in counts or sizes not produced by the application holder, for sale to hospitals and other institutions. The only change permitted to the FDA approved labeling for the specific product is the addition of the repacking entities name and address, under the manufacturers name and address on the FDA approved labeling. Under no circumstance should a repackaged product end up on a retail shelf, behind the drug counter or as an OTC drug in the retail section of any store.

The creation of counterfeit finished drug products as described above, is a Federal crime in violation of 21 U.S. Code § 331 (k), § 331 (a) and § 331 (b) and is punishable under of 21 U.S. Code § 333 by up to 10 years in prison and a $10,000.00 fine for each individual unit of product entered into the stream of commerce.

MTN has reviewed, documented, and collected the NIH and FDA database information as well as other evidence of the roles the various conspirators played in the scheme. IT’S A BOMBSHELL!

ONCE YOU UNDERSTAND THE LAWS/REGULATIONS SURROUNDING THIS, YOU WILL BE ARMED TO IDENTIFY A COUNTERFEIT RANITIDINE PRODUCT IN VIOLATION OF 21 U.S. Code § 331. THRU REVIEW OF THE SPL (STRUCTED PRODUCT LABELING) INFORMATION AND OTHER EVIDENCE IN OUR POSESSION. WITH THIS INFORMATION AND EVIDENCE IN HAND, YOU WILL BE ABLE TO DISCREDIT ANY AVERMENTS OF THESE DEFENDANTS CLAIMING THAT THEY HAD CEASED MARKETING A GIVEN PRODUCT AT THE TIME YOUR CLIENT CLAIMS TO HAVE PURCHASED THAT PRODUCT.

THE DEFENDANTS THAT PARTICIPATED IN THE SCHEME COMPLETELY IGNORED THE REQUIREMENTS OF THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA). ANY CLAIM OR AVERMENT MADE BY THESE DEFENDANTS THAT CONTRADICTS A PLAINTIFFS CLAIM REGARDING WHEN THEY PURCHASED A GIVEN PRODUCT, CAN BE REFUTED WITH OFFICAL RECORDS AND OTHER EVIDENCE IN OUR POSESSION. ADDITIONALLY, THE VERACITY OF ANY AVERMENT MADE BY THESE DEFENDANTS CAN BE CHALLANGED.

To provide clarity on WHAT THE DEFENDANTS ARE HIDING, you will receive John Ray’s White Paper prior to 12/16 for your review AND all of this ground breaking information will all be discussed in further detail on the Zantac/Ranitidine Whiteboard Wednesday.

Read More

WHAT THE ZANTAC GENERIC DEFENDANTS ARE HIDING

MASS TORT NEXUS IS ABOUT TO DROP A BOMBSHELL

After nine months and thousands of hours of research, MTN has finally unraveled the conspiracy (and identified most, if not all, of the conspirators) that led to the entry into interstate commerce of approximately 1000 counterfeit Ranitidine products, a crime, in violation of 21 U.S. Code § 331 (k).

MTN has reviewed all of the various NIH and FDA databases necessary to identify all Ranitidine NDC codes deactivated under Code I (this will all be explained).

What is the difference between the Recall of a Drug Product and an NDC Deactivation under Code I?

A recall of an approved drug product generally occurs when something new is discovered relevant to the risks associated with the approved product. A recall does not indicate that the product was unlawfully marketed in the first instance.

Conversely, the deactivation of an NDC code, for any reason other than Code “E” (expired), is prima facia evidence that the particular drug package or finished drug product was, at all times in commerce, in violation of one or more regulations that carry the force of law (civil) as well as other violations that can be subject to criminal prosecution. If you understand the laws and regulations, which you will after attending the Whiteboard Wednesday series on December 16th, you will be able to identify a counterfeit drug product as well as a product entered into the stream of commerce in violation of 21 U.S. Code § 331 (k), simply by reviewing the SPL dataset for that product, even if you are currently unfamiliar with the term “SPL date set”.

FYI: MTN has already identified all Ranitidine products entered into the stream of commerce in violation of 21 U.S. Code § 331 (k); however, we would like to teach you how to identify these violative products as the Zantac/Ranitidine litigation is not the only current litigation where these matters are relevant.

We did not end our review with the products the FDA has discovered and taken action via NDC code deactivation, we reviewed every label for every Ranitidine NDC code, ever marketed in the United States (including those in various NIH and FDA archives), in order to identify all products involved in what we now simply refer to as “the scheme”.

To the best of our knowledge, there have been no prior mass product liability litigations in which the FDA has deactivated a plurality of the products (by NDC code) long prior to the onset of the product liability litigation.

Among the benefits attendees will gain include:

  1. The ability to counter any Defendant that avers that they had stopped marketing a product before a given date, when a Plaintiff claims to have consumed that product. The “end marketing” date for any given drug product is part of an official record, for which the drug maker is responsible to maintain and update, the accuracy thereof being subject to oath under the penalty of perjury. The Defendant’s averments as to any alleged “end marketing date” are irrelevant, the official record governs. Defendants will be forced to pick their perjury: Did they perjure themselves in an official Federal Record, or are they now perjuring themselves before the MDL court?
  2. The ability to add allegations and claims to your complaints that are likely to make certain Defendants more amenable to settlement, sooner rather than later. Ranbaxy had to shell out approximately $525 billion in 2013, after the DOJ charged the drug maker with violations of 21 U.S. Code § 331 (k) (among other things). The breadth and scope of the 331 (k) charges brought against Ranbaxy pale in comparison to what MTN has discovered occurred among a large group of the Zantac generic conspirators. We have the proof!

This series of Whiteboard Wednesdays will only be open to MTN members or individual attorneys sponsored and vouched for by MTN members.

If you are not an MTN member, contact annemarie@masstortnexus.com or call 954-530-9892 to discover how to become a member of the largest network of mass tort attorneys in the country.

Upon completion of your Registration for Whiteboard Wednesday, you will receive a copy of our white paper that should be read prior to attending the first in this series of “Zantac Whiteboard Wednesdays”. We need to hit the ground running, and it is likely that you will need to act on behalf of your Zantac generic clients sooner rather than later, based on the knowledge and evidence provided.

Register now for the first in the series of Zantac Whiteboard Wednesdays, held on Wednesday, December 16th. The presentation runs from 2:00pm EST – 4:00pm EST with Q&A to follow.

Read More